Stroke Center

Sainte-Foy-lès-Lyon, France

Stroke Center

Sainte-Foy-lès-Lyon, France
SEARCH FILTERS
Time filter
Source Type

News Article | May 3, 2017
Site: www.eurekalert.org

VIDEO:  Helistroke is the doctor flying to the stroke patient. A Johns Hopkins Lifeline helicopter arrives to pick up and transport Dr. Ferdinand Hui to Washington, D.C. to treat a stroke... view more Flying a stroke specialist by helicopter to a nearby stroke patient for emergency care is feasible, saves money and, most importantly, gets critical care to patients faster than transporting the patient to a hospital first, according to a single-patient, proof-of-concept study by a Johns Hopkins Medicine research team. Although the study was not designed to show whether "helistroke service" would improve outcomes for patients, previous research has amply demonstrated that stroke victims do best when they are treated as quickly as possible -- ideally in 100 minutes or less. A report of the findings, published in the Journal of Neurointerventional Surgery on May 3, details what is believed to be the first test of transporting a physician by helicopter to perform a standard intervention for a stroke. "With the development of effective treatments, the most limiting factor to treating acute stroke is infrastructure -- we have to keep evolving our systems to get therapy to as many appropriate patients as possible," says Ferdinand K. Hui, M.D., associate professor of radiology and radiological science at the Johns Hopkins University School of Medicine. Hui, the report's first author, is the physician who was transported via helicopter for the study. In the traditional model of care, people experiencing an acute ischemic stroke (a cutoff of blood supply in a blood vessel to the brain) are taken to a hospital with a specialized center capable of performing a minimally invasive therapy in which a physician inserts a catheter into the groin and threads it up through blood vessels to the blood clot in the brain causing the stroke. Once the catheter is in place, the physician delivers drugs that break up the clot. Patient transport time, however, can be significant and, in many cases, stroke victims are first taken to a nearby community hospital, then transported to the specialized center, often further delaying time to treatment and lowering the odds of recovery or reduced disability. In a recent study analyzing the results of a global, multicenter trial, data show a 91 percent probability of favorable stroke outcome if patients' blood flow was restored within 150 minutes of stroke. The next 60 minutes of delay, researchers found, resulted in a 10 percent reduction of good outcome. An additional 60 minutes resulted in an additional 20 percent reduction of good outcome. For the best chance of a favorable outcome, preintervention time was calculated to be less than 100 minutes. To test the feasibility of a physician-to-patient model that could potentially improve outcomes for a time-sensitive procedure, investigators designed a study to fly Hui by Johns Hopkins Lifeline from Baltimore to a National Institutes of Health Stroke Center at Suburban Hospital in Washington, D.C. --39.4 miles away -- to treat a stroke victim. Suburban, part of the Johns Hopkins Health System, has radiologists and the necessary equipment to image blood vessels but no neurointerventional experts on hand to provide immediate, catheter-based treatment. A patient was eligible for treatment in the pilot study if he or she had a large vessel blockage and a National Institutes of Health Stroke Scale rating greater than eight, which is considered a severe stroke. The stroke scale is a 15-item neurologic examination used to evaluate the potential damage of stroke as soon as possible after it occurs. In January 2017, such a patient was identified at Suburban at 11:12 a.m. Scans to view the patient's blood vessels and brain tissue were initiated at 11:46 a.m. and completed at 11:58 a.m. Hui, who was at The Johns Hopkins Hospital in Baltimore, was alerted at 12:07 p.m. Johns Hopkins Lifeline, which provides critical care transportation, was called at 12:13 p.m. Weather clearance for helicopter takeoff was obtained at 12:24 p.m., and the helicopter flight from The Johns Hopkins Hospital to Suburban Hospital took 19 minutes. Hui inserted the catheter into the patient at 1:07 p.m. and completed treatment at 1:41 p.m. Total time between decision-to-treat and groin puncture was 43 minutes, and between decision-to-treat and groin closure was 77 minutes. These times are comparable with time to treatment in one institution without transfer. The patient received tissue Plasminogen Activator, a clot-dissolving drug, and improved clinically. Hui says the helistroke service model not only has the potential to reduce transport time and improve patient outcomes, but also could expand ideal standards of care to rural and other populations, where specialized care is limited. "Up until now, the model has been that the 'right place' was a central location, like a tertiary facility such as The Johns Hopkins Hospital," says Jim Scheulen, M.B.A., chief administrative officer of emergency medicine at The Johns Hopkins Hospital. "But what we have demonstrated here is that bringing the right resources in the right time to the patient may actually be a better approach than always moving the patient." Hui cautions that the helistroke service is not always the right or best choice: weather restrictions, specialist availability and transportation costs limit the use of the model. But flying a specialist to a patient may also eliminate some costs of nursing care, monitoring equipment, and the costs of ambulance services to one or more hospitals, as well as potentially fewer days of hospitalization and rehabilitation for stroke patients, he says. Although costs vary among regions and hospital networks, the cost of transferring a physician in this case was roughly 20 percent ($2,000-$3,000) of the average patient helicopter transfer cost ($6,500-$8,000) for the hospital network. Other authors on this paper include Amgad El Mekabaty, Kelvin Hong, Karen Horton, Victor Urrutia and Shawn Brast of Johns Hopkins Medicine; Jacky Schultz of Suburban Hospital; and Imama Naqvi, John K. Lynch and Zurab Nadareishvili of the National Institutes of Health.


News Article | May 4, 2017
Site: www.businesswire.com

STANFORD, Calif.--(BUSINESS WIRE)--Stanford Health Care announced that it has been recertified by The Joint Commission as an Advanced Comprehensive Stroke Center, a prestigious designation reserved for institutions with specific abilities to receive and treat the most complex stroke cases. Stanford Health Care was first recognized as a Joint Commission designated Primary Stroke Center in 2004. Stanford Health Care then received the first ever Advanced Comprehensive Stroke Center designation in the country in 2012, shortly after it was launched by The Joint Commission in partnership with the American Heart Association/American Stroke Association. Since then, recertification was awarded in both 2014 and 2016, as certification lasts for a two-year period for Joint Commission-accredited acute care hospitals. “This advanced recertification demonstrates the tremendous commitment and expertise of Stanford Health Care caregivers to ensuring that our stroke patients receive the best possible care and treatment,” said Gregory W. Albers, MD, director of the Stanford Stroke Center. “Our doctors provide advanced multidisciplinary care for all of our patients. We are very proud that our efforts to continuously advance care using a coordinated approach has led to national recognition of our success in caring for highly complex stroke patients.” When the team of Joint Commission surveyors came to Stanford in December, they found that the hospital met or exceeded all required standards, including advanced imaging and treatment capabilities, 24/7 availability of specialized treatments, participation in research and staff and physicians who have the unique education and competencies to care for complex stroke patients. Stanford Health Care uses a multidisciplinary group of specialists in the fields of vascular neurology, neurocritical care, neurosurgery, interventional neuroradiology, neuroimaging, neurology hospitalists, rehabilitation, emergency medicine, social work, pharmacy and nutrition, all using a coordinated approach to care for complex stroke patients. “One of the hallmarks of the Stanford program is its system for urgent transfers and immediate access to treatment,” Albers continued. “For patients experiencing an acute ischemic stroke, Stanford offers ultra RAPID transport coordinated by the Transfer Center, immediate access to advanced neuroimaging upon arrival and guaranteed ICU and Cath Lab access 24/7.” Over the past 25 years, the Stanford Stroke Center has provided care for more than 26,000 inpatients with cerebrovascular disorders. Nine physicians are on call for stroke emergencies at all times. In addition to providing patient care, the Stanford team has pioneered major advances in medical therapies, neurosurgical techniques and interventional neuroradiologic procedures, participated in more than 250 Clinical Stroke Trials and published more than 1,000 articles in scientific journals. The program receives extensive NIH grant support and contributes extensive research findings to the AHA's International Stroke Meeting each year. The Stanford Stroke Center has also been instrumental in developing national guidelines on stroke care beginning in 1993 with its guidelines on management of TIAs. Since then, it has developed or modified national guidelines for Stroke Treatment and Prevention, TIA Definition, Diagnosis and Evaluation and Stroke Prevention in Atrial Fibrillation. Stanford Health Care seeks to heal humanity through science and compassion, one patient at a time, through its commitment to care, educate and discover. Stanford Health Care delivers clinical innovation across its inpatient services, specialty health centers, physician offices, virtual care offerings and health plan programs. Stanford Health Care is part of Stanford Medicine, a leading academic health system that includes the Stanford University School of Medicine, Stanford Health Care, and Stanford Children’s Health, with Lucile Packard Children's Hospital. Stanford Medicine is renowned for breakthroughs in treating cancer, heart disease, brain disorders and surgical and medical conditions. For more information, visit: https://www.stanfordhealthcare.org.


News Article | November 21, 2016
Site: www.eurekalert.org

New York -- Nov.21, 2016 -- The Society of Vascular and Interventional Neurology (SVIN) announced the launch of Mission Thrombectomy 2020, an initiative to enhance global efforts to improve stroke care worldwide by increasing the rate of stroke thrombectomy for eligible patients from less than 100,000 procedures today to 202,000 annually by 2020 and thereby reducing global stroke disability. Stroke Thrombectomy, also known as Mechanical Thrombectomy, is the new highly effective standard of care that reverses paralysis from stroke in over 60% of patients if done by experts within 6 hours of stroke symptoms. The initiative was unveiled at the SVIN 9th Annual Meeting and 4th Annual Stroke Center Workshop, which took place from November 16-19, 2016 in Brooklyn, New York. "In 2015, mechanical thrombectomy was definitively proven to be enormously beneficial in reversing stroke disability and become standard of care for stroke patients with blockage of one of the main brain arteries. This has revolutionized the treatment for such patients," said Dr. Dileep Yavagal, MD, Past President of SVIN, who is leading this effort. "SVIN has set an ambitious worldwide goal to treat every eligible stroke patients emergently with mechanical thrombectomy, but this can only be achieved if we maximize access to hospitals with mechanical thrombectomy capability of severe stroke with within six hours of their symptoms." In order to maximize access to thrombectomy for the potential 1.7 million patients worldside with stroke due to a large artery blockage, SVIN aims to partner with several non-profit medical societies, governmental and industry collaborators worldwide to achieve their initiative by focusing on efforts to improve public awareness for stroke symptoms, supporting legislation to encourage rapid triage of stroke patients, establishing financial initiatives to improve access to care for countries without health insurance and encouraging the development of new technologies to improve stroke assessment and treatment. Currently less than 100,000 procedures are performed worldwide in 2016. One supporter announced at the meeting was Neural Analytics which demonstrated its Lucid™ System, a device designed to help improve rapid assessment of patients with brain blood flow disorders, at the meeting. "Mission Thrombectomy 2020 advances the overall mission of SVIN of innovation to improve outcomes of the largest number of stroke patients all over the world" said Raul Nogueira, MD, President of SVIN. "This campaign will consolidate various efforts from multiple stakeholders with a clear patient metric to be achieved in 3 years." "We are pleased to support SVIN on this important initiative to improve stroke treatment worldwide and help reduce the disability associated with this condition," said Robert Hamilton, Co-Founder & Chief Science Officer of Neural Analytics. "A critical component for effective stroke treatment is determining an accurate diagnosis as quickly as possible in settings inside and outside the hospital. Globally each year, strokes affect about 16 million people and kill an estimated 5.7 million. The annual U.S. healthcare overall cost due to stroke is $104 billion. Stroke is a very time sensitive disease and requires intervention within six hours. Without appropriate diagnosis and treatment, a majority of surviving stroke patients suffer permanent disability. Despite the recent advances of mechanical thromectomy, which reduces disability and saves lives, less than 10 percent of eligible stroke patients are treated surgically due to the lack of a portable diagnostic device for early detection.1,2,3,4 SVIN is the premier society worldwide for medical professionals engaged in interventional neurology and stroke care. Our mission to promote excellence in the field of interventional treatment of neurovascular diseases by neurologists. The society represents the advancement of interventional neurology through education, research and advocacy with the ultimate goal of improving clinical care and outcomes of patients with stroke and cerebrovascular diseases. The SVIN Annual Meeting is a premier academic venue with scientific presentations covering the full spectrum of cerebrovascular diseases and stroke. Participants have the opportunity to discuss embolectomy, aneurysms and AVMs, subarachnoid and intracranial hemorrhage, endovascular saves and innovative approaches, new device review, international perspectives, and other-related topics. For further information about SVIN, please visit http://www. or find us on Facebook, Twitter or LinkedIn. 1. Ganesalingam, J. Cost Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke. Stroke. 2015 Sep;46(9):2591-8. doi: 10.1161/STROKEAHA.115.009396. Epub 2015 Aug 6. 2. Saver, J. et. Al. Stent Retriever Thrombectomy after Intraveneous t-PA vs. t_PA alone in stroke. N Engl J Med 2015; 372:2285-2295 3. Ovbiagele, B. et. Al Forecasting the Future of Stroke in the United States. Stroke. 2013. http://stroke.


HOUSTON--(BUSINESS WIRE)--Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced the presentation of the results of the ASTER Trial, the first independent, prospective, randomized trial comparing the use of Penumbra’s aspiration system to stent retriever, in the opening plenary session at the International Stroke Conference in Houston, Texas. The ASTER Trial provides additional evidence of Penumbra’s aspiration system as an effective frontline thrombectomy approach for acute ischemic stroke as part of the ADAPT (A Direct Aspiration, First Pass Technique) technique. “The ASTER study provides evidence that starting with Penumbra aspiration first as part of the ADAPT technique is similar to the stent retriever technique,” said Michel Piotin, MD, principal investigator and interventional neuroradiologist at Rothschild Fondation Hospital in Paris. “The ADAPT technique offers the possibility to easily add a stent retriever following Penumbra aspiration if needed, leading to time savings.” The data showed that the ADAPT technique compared favorably: 85.4 percent of patients treated with Penumbra’s aspiration system achieved the primary endpoint of TICI 2b/3 at the end of the procedure compared with 83.1 percent of patients treated with stent retrievers (p=0.53). Moreover, 63.0 percent of patients treated with Penumbra’s aspiration system achieved the secondary endpoint of TICI 2b/3 after frontline treatment compared to 67.7 percent with stent retrievers (p=0.33). “The ASTER Trial shows no significant difference in revascularization rate and safety using either thrombectomy technique – Penumbra aspiration and stent retrievers – for acute ischemic stroke patients with large vessel occlusions,” said Bertrand Lapergue, MD, PhD, Division of Neurology, Stroke Center, Foch Hospital, University Versailles Saint-Quentin en Yvelines (France) and scientific coordinator for the study. “The broad eligibility criteria achieved in the ASTER Trial make the results generalizable to the majority of stroke patients with large vessel occlusions.” Secondary safety endpoints presented, including embolization in new territory (ENT) and symptomatic intracranial hemorrhage (sICH), were not statistically different between the two arms. “The ASTER Trial builds on the results of the 3D Trial, providing additional evidence supporting the use of Penumbra System direct aspiration devices as a first-line treatment for acute ischemic stroke patients,” said Adam Elsesser, chairman, chief executive officer and president of Penumbra. “The ADAPT technique with the Penumbra System as a frontline approach together with complementary adjunctive devices when needed offers a cost-effective solution for treating stroke patients, which is critical as patient access to mechanical thrombectomy is further expanded.” The ASTER (Adapt versus StEnt Retriever) Trial is a prospective, randomized controlled study that compared the safety and efficacy of the Penumbra aspiration system used frontline as part of the ADAPT technique versus stent retrievers. The primary endpoint was end of procedure revascularization (TICI 2b/3). The study enrolled 381 patients at eight centers in France over 12 months beginning in October 2015. Penumbra provided an institutional grant to support the ASTER Trial. The Penumbra System consists of large diameter, highly flexible, and reliably trackable reperfusion catheters that utilize the full aspiration power of the Penumbra Pump MAX™ through its Hi-Flow Aspiration Tubing. The Penumbra System enables physicians to use aspiration, which acts like a minimally invasive “vacuum” inside the artery, to remove stroke-causing blood clots from the brain safely and effectively. The Penumbra System is the only FDA cleared integrated aspiration system for the revascularization of ischemic stroke patients. Penumbra, Inc., headquartered in Alameda, California, is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices. The company has a broad portfolio of products that address challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. Penumbra sells its products to hospitals primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets. Penumbra, the Penumbra logo, ACE, and Pump MAX are trademarks of Penumbra, Inc. Other trademarks are the property of their respective owners. Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; and potential adverse regulatory actions. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2015. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.


HOUSTON - Feb. 22, 2017 - Penumbra, Inc. (NYSE: PEN), a global interventional therapies company, today announced the presentation of the results of the ASTER Trial, the first independent, prospective, randomized trial comparing the use of Penumbra's aspiration system to stent retriever, in the opening plenary session at the International Stroke Conference in Houston, Texas. The ASTER Trial provides additional evidence of Penumbra's aspiration system as an effective frontline thrombectomy approach for acute ischemic stroke as part of the ADAPT (A Direct Aspiration, First Pass Technique) technique. "The ASTER study provides evidence that starting with Penumbra aspiration first as part of the ADAPT technique is similar to the stent retriever technique," said Michel Piotin, MD, principal investigator and interventional neuroradiologist at Rothschild Fondation Hospital in Paris. "The ADAPT technique offers the possibility to easily add a stent retriever following Penumbra aspiration if needed, leading to time savings." The data showed that the ADAPT technique compared favorably: 85.4 percent of patients treated with Penumbra's aspiration system achieved the primary endpoint of TICI 2b/3 at the end of the procedure compared with 83.1 percent of patients treated with stent retrievers (p=0.53). Moreover, 63.0 percent of patients treated with Penumbra's aspiration system achieved the secondary endpoint of TICI 2b/3 after frontline treatment compared to 67.7 percent with stent retrievers (p=0.33). "The ASTER Trial shows no significant difference in revascularization rate and safety using either thrombectomy technique - Penumbra aspiration and stent retrievers - for acute ischemic stroke patients with large vessel occlusions," said Bertrand Lapergue, MD, PhD, Division of Neurology, Stroke Center, Foch Hospital, University Versailles Saint-Quentin en Yvelines (France) and scientific coordinator for the study. "The broad eligibility criteria achieved in the ASTER Trial make the results generalizable to the majority of stroke patients with large vessel occlusions." Secondary safety endpoints presented, including embolization in new territory (ENT) and symptomatic intracranial hemorrhage (sICH), were not statistically different between the two arms. "The ASTER Trial builds on the results of the 3D Trial, providing additional evidence supporting the use of Penumbra System direct aspiration devices as a first-line treatment for acute ischemic stroke patients," said Adam Elsesser, chairman, chief executive officer and president of Penumbra. "The ADAPT technique with the Penumbra System as a frontline approach together with complementary adjunctive devices when needed offers a cost-effective solution for treating stroke patients, which is critical as patient access to mechanical thrombectomy is further expanded." The ASTER (Adapt versus StEnt Retriever) Trial is a prospective, randomized controlled study that compared the safety and efficacy of the Penumbra aspiration system used frontline as part of the ADAPT technique versus stent retrievers. The primary endpoint was end of procedure revascularization (TICI 2b/3). The study enrolled 381 patients at eight centers in France over 12 months beginning in October 2015. Penumbra provided an institutional grant to support the ASTER Trial. The Penumbra System consists of large diameter, highly flexible, and reliably trackable reperfusion catheters that utilize the full aspiration power of the Penumbra Pump MAX™ through its Hi-Flow Aspiration Tubing. The Penumbra System enables physicians to use aspiration, which acts like a minimally invasive "vacuum" inside the artery, to remove stroke-causing blood clots from the brain safely and effectively. The Penumbra System is the only FDA cleared integrated aspiration system for the revascularization of ischemic stroke patients. Penumbra, Inc., headquartered in Alameda, California, is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices. The company has a broad portfolio of products that address challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. Penumbra sells its products to hospitals primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets. Penumbra, the Penumbra logo, ACE, and Pump MAX are trademarks of Penumbra, Inc. Other trademarks are the property of their respective owners. Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statement s. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; and potential adverse regulatory actions. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2015. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.


MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--SanBio, Inc., a scientific leader in regenerative medicine for neurological disorders, today announced that a recent publication of its novel stem cell treatment, SB623, for patients following a stroke, has received a prestigious award from the American Heart Association. The scientific article, “Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study,” was the third prize winner of the 2016 Stroke Progress and Innovation Award. The Progress and Innovation Awards are offered by Stroke, a leading scientific journal addressing the diagnosis and treatment of cerebrovascular diseases, jointly with the American Heart Association and American Stroke Association. Previous award winners have established important standards of care in neurology, including Activase (alteplase) and induced hypothermia treatment. Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, said, “This prize from the American Heart Association recognizes the innovation of our stem cell treatment, SB623, and its potential to treat patients suffering from chronic physical impairments following ischemic stroke. The results of this study are encouraging to all those suffering from the long-term effects of stroke as well as the medical community working to advance treatment options.” The clinical trial was a Phase 1/2a, open-label, single-arm, dose escalation study of 18 patients with chronic motor deficits present for at least six months following an ischemic stroke. Patients received precisely targeted injections of SB623 cells directly into the neural tissue surrounding the damaged area of the brain. Dr. Gary Steinberg, Chairman of the Department of Neurosurgery at the Stanford University School of Medicine and Co-Director of the Stanford Stroke Center, served as Principal Investigator for the clinical trial. Results for subjects who completed the single arm Phase 1/2a study demonstrated statistically significant improvement in motor function, evaluated using the European Stroke Scale, National Institutes of Health Stroke Scale, the Fugl-Meyer total score and the Fugl-Meyer motor function total score. The data also showed that the treatment was generally safe and well-tolerated by the trial participants. As lead author of the scientific article, Dr. Steinberg accepted the award at the recent International Stroke Conference in Houston. SanBio is a regenerative medicine company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from stroke, with its joint development partner, Sumitomo Dainippon Pharma Co., Ltd., in the United States and Canada. SanBio is also implementing a global Phase 2 clinical trial using SB623 in the United States and Japan for the treatment of motor impairment resulting from traumatic brain injury. More information about SanBio is available at www.sanbio.com.


News Article | November 2, 2016
Site: www.PR.com

Whether trying to find a physician, checking our visiting hours, locating an address of an off-site facility or trying to access your medical records, the new website is fast and consumer-friendly. Oceanside, NY, November 02, 2016 --( Whether trying to find a physician, checking our visiting hours, locating an address of an off-site facility or trying to access your medical records, the new website is fast and consumer-friendly. And it also is now all available on smart phones in a mobile-friendly format. Contact information for more than 900 physicians affiliated with the hospital can be quickly located in the new online physician directory. Detailed information about South Nassau's many services, from cancer care to orthopedics, maternity, weight loss, geriatrics and the Trauma Center, can also be found on the website. "Our goal is to make the patient experience online as easy as possible and our redesigned website strives to keep our customers and the communities we serve in the forefront of all we do," said Richard J. Murphy, South Nassau's President & CEO. South Nassau's new website features a simplified navigation, making it easier for website visitors to locate content that meets their needs and answers their questions, while connecting them to the complete roster of physicians as well as specialized healthcare services located on the hospital's main campus in Oceanside or conveniently based in the vicinity of the hospital. Site navigation has been completely reorganized so that visitors have a hassle-free, efficient browsing experience, accessing health information, hospital news and events and other featured content with just one click. South Nassau's website averages 21,000 users per month. Embracing the increasing use of hand-held devices, southnassau.org includes an optimized experience for viewing on any device – mobile, tablet or PC – at home, at work or on the go. Wax Custom Communications, a Miami, FL-based multi-channel marketing firm with offices in Louisville and San Diego, assisted with the creation and development of the new web site. Designated a Magnet® hospital by the American Nurses Credentialing Center (ANCC), South Nassau® Communities Hospital is one of the region's largest hospitals, with 455 beds, more than 900 physicians and 3,500 employees. Located in Oceanside, NY, the hospital is an acute-care, not-for-profit teaching hospital that provides state-of-the-art care in cardiac, oncologic, orthopedic, bariatric, pain management, mental health and emergency services. In addition to its extensive outpatient specialty centers, South Nassau provides emergency and elective angioplasty, and offers Novalis Tx™ and Gamma Knife® radiosurgery technologies. A Level II Trauma Center verified by the American College of Surgeons, South Nassau is a designated Stroke Center by the New York State Department of Health and Comprehensive Community Cancer Center by the American College of Surgeons, and is an accredited center of the Metabolic and Bariatric Surgery Association and Quality Improvement Program. In addition, the hospital has been awarded the Joint Commission's gold seal of approval as a Top Performer on Key Quality Measures, including heart attack, heart failure, pneumonia and surgical care; and disease-specific care for hip and joint replacement, wound care and end-stage renal disease. Oceanside, NY, November 02, 2016 --( PR.com )-- South Nassau Communities Hospital has launched a totally redesigned and mobile friendly website to make it easier for patients and visitors to find the services and information they need to stay healthy.Whether trying to find a physician, checking our visiting hours, locating an address of an off-site facility or trying to access your medical records, the new website is fast and consumer-friendly. And it also is now all available on smart phones in a mobile-friendly format.Contact information for more than 900 physicians affiliated with the hospital can be quickly located in the new online physician directory. Detailed information about South Nassau's many services, from cancer care to orthopedics, maternity, weight loss, geriatrics and the Trauma Center, can also be found on the website."Our goal is to make the patient experience online as easy as possible and our redesigned website strives to keep our customers and the communities we serve in the forefront of all we do," said Richard J. Murphy, South Nassau's President & CEO.South Nassau's new website features a simplified navigation, making it easier for website visitors to locate content that meets their needs and answers their questions, while connecting them to the complete roster of physicians as well as specialized healthcare services located on the hospital's main campus in Oceanside or conveniently based in the vicinity of the hospital.Site navigation has been completely reorganized so that visitors have a hassle-free, efficient browsing experience, accessing health information, hospital news and events and other featured content with just one click. South Nassau's website averages 21,000 users per month.Embracing the increasing use of hand-held devices, southnassau.org includes an optimized experience for viewing on any device – mobile, tablet or PC – at home, at work or on the go. Wax Custom Communications, a Miami, FL-based multi-channel marketing firm with offices in Louisville and San Diego, assisted with the creation and development of the new web site.Designated a Magnet® hospital by the American Nurses Credentialing Center (ANCC), South Nassau® Communities Hospital is one of the region's largest hospitals, with 455 beds, more than 900 physicians and 3,500 employees. Located in Oceanside, NY, the hospital is an acute-care, not-for-profit teaching hospital that provides state-of-the-art care in cardiac, oncologic, orthopedic, bariatric, pain management, mental health and emergency services. In addition to its extensive outpatient specialty centers, South Nassau provides emergency and elective angioplasty, and offers Novalis Tx™ and Gamma Knife® radiosurgery technologies. A Level II Trauma Center verified by the American College of Surgeons, South Nassau is a designated Stroke Center by the New York State Department of Health and Comprehensive Community Cancer Center by the American College of Surgeons, and is an accredited center of the Metabolic and Bariatric Surgery Association and Quality Improvement Program. In addition, the hospital has been awarded the Joint Commission's gold seal of approval as a Top Performer on Key Quality Measures, including heart attack, heart failure, pneumonia and surgical care; and disease-specific care for hip and joint replacement, wound care and end-stage renal disease. Click here to view the list of recent Press Releases from South Nassau Communities Hospital


News Article | December 15, 2016
Site: www.businesswire.com

NEW YORK--(BUSINESS WIRE)--Jeremy B. Strauss, CEO of The Grand Healthcare System, received the Healthcare Heroes Award at an awards dinner held at Douglaston Manor, Queens, NY on December 6, 2016. Strauss was among several leading healthcare professionals in Queens who were honored for their contributions to the healthcare field. Strauss’ career began in 1995 at the non-profit Hebrew Academy for Special Children where he had a significant role in creating specialized residences for the mentally disabled. He entered the nursing home profession in 1996 as assistant director of admissions. He later become an owner and operator of his first home eight years later, and a partner in the purchase and operation of more than 30 skilled nursing facilities. As CEO of The Grand Healthcare System, Strauss brings his own brand of unparalleled service to his skilled nursing and rehabilitation facilities. He believes in treating every guest like family, focusing his attention on their clinical needs while understanding the importance of personal needs and customer service. Strauss graduated from Yeshiva University with a finance and economics degree. He has volunteered as an EMT for more than 25 years and he sits on the boards of several charitable institutions and schools. What distinguishes The Grand Healthcare System from others is its quality of care and the attention to detail Strauss gives to everything from cozy furnishings to modern amenities that go well beyond expectations. Strauss and his colleagues often say, “ At The Grand, our guests always come first.” In response to the increasing demand for stroke rehabilitation in New York City, Strauss recently launched The Walter Strauss Stroke Center. The new facility, located at The Grand Rehabilitation and Nursing at Queens, is spearheaded by an interdisciplinary team of medical professionals and nurses specializing in stroke rehabilitation and recovery. Recovery programs focus on walking, eating, dressing and communicating. In addition to Strauss, the 2016 Healthcare Heroes Award was presented to CEOs Dr. Steven Mendelsohn, Zwanger-Pesiri Radiology; Michael Dowling, Northwell Health; Gerald Walsh, St. John’s Episcopal Hospital; Sean Granahan, The Floating Hospital; Dr. Navarra Rodriguez of ACPNY and Emblem Health; and Jugal Agarwal, Atlantic Dialysis. Keynote speaker was New York City’s First Lady Chirlane McCray. The Grand Healthcare System offers a full continuum of premium healthcare and specialty care services throughout its state-of-the-art, all-inclusive health facilities in Queens, Pawling, Poughkeepsie, Guilderland Center, Chittenango and Rome, NY. Nursing and rehabilitation services and programs include stroke rehabilitation at The Walter Strauss Stroke Center, amputee therapy and training program, bariatric rehabilitation, cardiac therapy, complex medical care program, hip repair and joint replacement recovery program, IV antibiotic therapy, medical nutrition therapy, medical shuttle service and transportation vans. For more information call (718) 215-6000 or visit www.thegrandhealthcare.com.


Proceeds from the 4th Annual Casino Royale will support South Nassau's Emergency Department Expansion Campaign. The campaign is a five-year, $10 million fundraising initiative to help pay for a $60 million renovation of the ED. Oceanside, NY, February 26, 2017 --( "Tammy has been a special friend to South Nassau Communities Hospital for a number of years and has shown tremendous dedication to our hospital and our mission," said South Nassau's president and CEO, Richard J. Murphy. "She has gone above and beyond for our patients and has helped raise awareness and funds for the work we do. We appreciate her support." Proceeds from the 4th Annual Casino Royale will support South Nassau's Emergency Department Expansion Campaign. The campaign is a five-year, $10 million fundraising initiative to help pay for a $60 million renovation of the Oceanside Emergency Department, serving all residents of the South Shore from Queens to Suffolk. The expansion project will nearly double the size of the Emergency Department, providing space to accommodate a projected 80,000 patient visits each year as well as establishing dedicated areas for behavioral health and pediatric emergencies. Casino Night attendees will put their gambling savvy and instincts to the test at Vegas-style Black Jack, Craps, and Roulette tables, and "Top Hat Bingo," in which the bingo game winner receives a top hat filled with casino money and prizes. When they're not at the tables or beating the odds, attendees will be treated to choice cocktails, a delectable buffet and other gaming for great prizes, including premiere Mets tickets and a 48-inch "smart" television. Tickets for the event can still be purchased in advance for $100 per person, or $150 at the door, which includes a full buffet, drinks and $200 in play money. Doors open at 6PM. To purchase tickets in advance or for more information, call 516-377-5360. Ms. Marshall and her team at Maple Point has raised over $72,000 on behalf of South Nassau through multiple fundraisers she has organized over the past several years. This year, she expanded her efforts, launching a host of new events that have increased donations. Ms. Marshall, a resident of Massapequa, is a dedicated healthcare professional with more than 20 years of experience that includes serving 15 years as a critical care nurse at Southside Hospital in Bay Shore, NY. It was during that time that Ms. Marshall, developed an inclination for healthcare administration, especially in long-term senior care. After serving as a manager of assisted living residences based in San Francisco, Calif., as well as on Long Island, she was named executive director of Maple Pointe. In addition to her responsibilities as executive director of Maple Pointe, Ms. Marshall serves on the board of directors as well as executive committee of the New York State Center for Assisted Living. She and her patient care team at Maple Pointe are known for their innovation in developing processes, procedures and operations that result in standard-setting quality, safety and patient satisfaction in long-term senior care. Under Ms. Marshall's leadership, Maple Pointe is a two-time recipient of the prestigious Innovative Practice Award for long-term care providers in New York, receiving the award for excellence in staff retention and for implementing a program designed to reduce the incidence of falls among senior citizens. The staff retention program received such broad acclaim that it was featured in Provider magazine, the monthly journal of the National Center for Assisted Living. South Nassau's Emergency Services Department is the busiest community hospital emergency services department in Nassau County. Presently serving more than 65,000 patients annually, the department's staff includes board-certified, residency-trained emergency medicine physicians as well as nurses and physicians' assistants who have been specially-trained in emergency medical care. The department is designated a regional Stroke Center by the New York State Department of Health and is southern Nassau County's only Trauma Level II Center. The department has over 35 large independent treatment bays and specialty areas, including Pediatrics and Behavioral Health, as well as its own dedicated Computerized Radiology Suite for rapid access for testing and results. Oceanside, NY, February 26, 2017 --( PR.com )-- Tammy Marshall, RN, Executive Director of Maple Pointe Assisted Living in Rockville Centre, one of New York's foremost leaders in long-term care for seniors, is the honoree of South Nassau Communities Hospital's 4th Annual Casino Royale to be held Thursday, March 9, at the Coral House in Baldwin (NY)."Tammy has been a special friend to South Nassau Communities Hospital for a number of years and has shown tremendous dedication to our hospital and our mission," said South Nassau's president and CEO, Richard J. Murphy. "She has gone above and beyond for our patients and has helped raise awareness and funds for the work we do. We appreciate her support."Proceeds from the 4th Annual Casino Royale will support South Nassau's Emergency Department Expansion Campaign. The campaign is a five-year, $10 million fundraising initiative to help pay for a $60 million renovation of the Oceanside Emergency Department, serving all residents of the South Shore from Queens to Suffolk. The expansion project will nearly double the size of the Emergency Department, providing space to accommodate a projected 80,000 patient visits each year as well as establishing dedicated areas for behavioral health and pediatric emergencies.Casino Night attendees will put their gambling savvy and instincts to the test at Vegas-style Black Jack, Craps, and Roulette tables, and "Top Hat Bingo," in which the bingo game winner receives a top hat filled with casino money and prizes. When they're not at the tables or beating the odds, attendees will be treated to choice cocktails, a delectable buffet and other gaming for great prizes, including premiere Mets tickets and a 48-inch "smart" television. Tickets for the event can still be purchased in advance for $100 per person, or $150 at the door, which includes a full buffet, drinks and $200 in play money.Doors open at 6PM. To purchase tickets in advance or for more information, call 516-377-5360.Ms. Marshall and her team at Maple Point has raised over $72,000 on behalf of South Nassau through multiple fundraisers she has organized over the past several years. This year, she expanded her efforts, launching a host of new events that have increased donations.Ms. Marshall, a resident of Massapequa, is a dedicated healthcare professional with more than 20 years of experience that includes serving 15 years as a critical care nurse at Southside Hospital in Bay Shore, NY. It was during that time that Ms. Marshall, developed an inclination for healthcare administration, especially in long-term senior care. After serving as a manager of assisted living residences based in San Francisco, Calif., as well as on Long Island, she was named executive director of Maple Pointe.In addition to her responsibilities as executive director of Maple Pointe, Ms. Marshall serves on the board of directors as well as executive committee of the New York State Center for Assisted Living. She and her patient care team at Maple Pointe are known for their innovation in developing processes, procedures and operations that result in standard-setting quality, safety and patient satisfaction in long-term senior care. Under Ms. Marshall's leadership, Maple Pointe is a two-time recipient of the prestigious Innovative Practice Award for long-term care providers in New York, receiving the award for excellence in staff retention and for implementing a program designed to reduce the incidence of falls among senior citizens. The staff retention program received such broad acclaim that it was featured in Provider magazine, the monthly journal of the National Center for Assisted Living.South Nassau's Emergency Services Department is the busiest community hospital emergency services department in Nassau County. Presently serving more than 65,000 patients annually, the department's staff includes board-certified, residency-trained emergency medicine physicians as well as nurses and physicians' assistants who have been specially-trained in emergency medical care. The department is designated a regional Stroke Center by the New York State Department of Health and is southern Nassau County's only Trauma Level II Center. The department has over 35 large independent treatment bays and specialty areas, including Pediatrics and Behavioral Health, as well as its own dedicated Computerized Radiology Suite for rapid access for testing and results. Click here to view the list of recent Press Releases from South Nassau Communities Hospital


News Article | November 7, 2016
Site: www.prweb.com

HMO’s, PPO’s, co-pays, co-insurance… Yes, open enrollment time is here, a time when millions of consumers will be overwhelmed with complex information on policies, premiums, and coverage that can have dramatic financial implications down the road. To clear confusion and help with decision-making, White Plains Hospital is offering a free, downloadable guide for consumers to help them make informed decisions. The guide is available through the Hospital’s website at http://www.wphospital.org/insuranceguide. “Choosing A Health Plan: It Pays to Know Your Options” offers the following information: The guide was written to help consumers make more informed health plan choices, whether they purchase coverage through their employer or on the New York State of Health marketplace. “Our goal is to help people in the community avoid unexpected healthcare costs,” says Joseph J. Guarracino, CFO of White Plains Hospital. “Whether you are using an employer-provided plan, or evaluating coverage on the health insurance exchange, it’s important to consider how much coverage you might need, how much your monthly premium will cover, and what you may be responsible for if you have a significant health event.” Since the Affordable Care Act created state health insurance exchanges, the number of people with health insurance has grown. In 2015, the percentage of people without health insurance coverage for the entire calendar year was 9.1%, or 29 million, lower than the rate and number of uninsured in 2014 (10.4% or 33 million), according to the US Census Bureau. The US Census also notes that the percentage of people with health insurance coverage for all or part of 2015 was 90.9%, higher than the rate in 2014 (89.6%). But, as more and more consumers are getting the health coverage they need, the decision-making process is difficult and available information is hard to comprehend. A 2016 Harris Poll reported on PlanSponsor.com found that nearly half (49%) of employees eligible for employer-sponsored benefits said making health insurance decisions is “always stressful,” and 41% of employees found their companies’ open enrollment process “very confusing.” The health insurance guide can be downloaded through the White Plains Hospital website, and will be available in waiting rooms at the Hospital, and through its outpatient medical facilities in New Rochelle and Armonk through the end of January 2017. White Plains Hospital (WPH) is a proud member of the Montefiore Health System, serving as its tertiary hub of advanced care in the Hudson Valley. WPH is a 292-bed not-for-profit health care organization with the primary mission of providing exceptional acute and preventive medical care to all people who live in, work in or visit Westchester County and its surrounding areas. Centers of Excellence include the Center for Cancer Care, The William & Sylvia Silberstein Neonatal & Maternity Center and The Ruth and Jerome A. Siegel Stroke Center. The Hospital’s Flanzer Emergency Department is the busiest in Westchester County, seeing nearly 57,000 visits a year. White Plains Hospital performs lifesaving emergency and elective angioplasty in its Joan and Alan Herfort, M.D. Cardiac Catheterization Laboratory and Marie Promuto Cardiac Catheterization Laboratory. White Plains Hospital also has outpatient medical facilities in Armonk and New Rochelle. The Hospital is fully accredited by the Joint Commission and earned its recognition as a Top Performer for Key Quality Measures® in 2015 and 2013. The Hospital is also an eleven-time winner of the Consumer Choice Award, an honor given to the nation’s top hospitals by the National Research Corporation, and received Magnet® designation in 2012 from the American Nurses Credentialing Center (ANCC). In 2014 and 2016, White Plains Hospital received the Outstanding Patient Experience Award from Healthgrades®, given to only 10% of hospitals nationwide. For additional information, visit http://www.wphospital.org.

Loading Stroke Center collaborators
Loading Stroke Center collaborators